Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 21:01:21 28/06/2024 BST After market 00:00:10
27.98 USD +0.65% Intraday chart for Pfizer, Inc. 27.97 -0.04%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Pfizer: CHMP recommends new Covid vaccine CF
Would you like some more inflation? Our Logo
EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older RE
Pfizer Inc.(NYSE:PFE) dropped from Russell Top 50 Index CI
Pfizer, BioNTech Get Positive Committee Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in European Union MT
Pfizer, BioNTech Get Positive CHMP Opinion for New Covid-19 Vaccine DJ
Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer CI
GSK Shares Slump After CDC Narrows Age Recommendation for RSV Shots DJ
CDC Updates RSV Shot Recommendation Among the Elderly; Vaccine Makers Mixed Pre-Bell MT
Nervy trade in London before US data AN
Pfizer Keeps Q3 Dividend at $0.42 a Share, Payable Sept. 3 to Holders of Record July 26 MT
Pfizer Inc. Declares Third-Quarter 2024 Dividend on the Company?s Common Stock, Payable on September 3, 2024 CI
Moderna Shares Fall as RSV Shot Efficacy Lags Behind Rivals' Vaccines, CDC Data Shows MT
CDC advisers narrow age recommendation for RSV shots in US RE
US CDC Advisers Recommend RSV Vaccine For Adults Aged 60 Years Of Age And Above RE
Moderna RSV Shot Efficacy Lower Than Rivals' Vaccines, CDC Data Shows MT
Moderna RSV Shot Efficacy Lower Than Rivals', CDC Data Shows; Shares Down 9.5% MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes CI
CVRx, Inc. Announces Appointment of Robert Allen John as Chief Revenue Officer, Effective June 27, 2024 CI
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit RE
Sarepta surges as investors cheer expanded use of gene therapy RE
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
27.98 USD
Average target price
31.92 USD
Spread / Average Target
+14.07%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. Analysts Expect Pfizer COVID-19 Pill to Provide Revenue Boost in 2022